<SEC-DOCUMENT>0001019687-14-002517.txt : 20140626
<SEC-HEADER>0001019687-14-002517.hdr.sgml : 20140626
<ACCEPTANCE-DATETIME>20140623093021
ACCESSION NUMBER:		0001019687-14-002517
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140619
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140623
DATE AS OF CHANGE:		20140623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		14934283

	BUSINESS ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k-061914.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
June 19, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 30%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">000-21846</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 48%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 48%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8910 University Center Lane, Suite 660</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Diego, California</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">92122</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Zip Code)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 96%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">p</FONT>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">p</FONT>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">p</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">p</FONT>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Form 8-K and other reports filed by Registrant from time
to time with the Securities and Exchange Commission (collectively, the &quot;Filings&quot;) contain or may contain forward-looking
statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well
as estimates and assumptions made by Registrant's management. When used in the Filings the words &quot;anticipate,&rdquo; &quot;believe,&quot;
&quot;estimate,&quot; &quot;expect,&quot; &quot;future,&quot; &quot;intend,&quot; &quot;plan&quot; or the negative of these terms
and similar expressions as they relate to Registrant or Registrant's management identify forward-looking statements. Such statements
reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other
factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired
by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although Registrant believes that the expectations reflected
in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or
achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend
to update any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-size: 10pt"><B>ITEM 8.01</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Other Events</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 19, 2014, Aethlon Medical, Inc.
(the &ldquo;Registrant&rdquo;) made a presentation at the Wall Street Analyst Forum. In connection therewith, on June 17, 2014,
the Registrant issued the Press Release attached to this Current Report as Exhibit 99.1, in which it announced the presentation.
A copy of the presentation materials was made available on the Registrant&rsquo;s website (<U>www.aethlonmedical.com</U>) under
the Events and Presentations section of the Investor Relations page on June 20, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the Press Release
does not purport to be complete and is qualified in its entirety by the Press Release attached as Exhibit 99.1 hereto. Readers
should review the Press Release for a complete understanding of its content and the matters announced and described in the Press
Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-size: 10pt"><B>ITEM 9.01</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Exhibit No.</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Press Release dated June 17, 2014</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">&nbsp;AETHLON MEDICAL, INC.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top"></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:&nbsp;<U>/s/ James B. Frakes</U></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">James B. Frakes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Dated: June 23, 2014</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="aethlon_logo" STYLE="height: 72px; width: 193px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical to Present at The Wall
Street Analyst Forum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SAN DIEGO</B> &ndash; June 17, 2014
&ndash; Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious
disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer,
Jim Joyce, will present at The Wall Street Analyst Forum 25<SUP>th</SUP> Annual Institutional Investor Conference on Thursday,
June 19<SUP>th</SUP>, at 12:05 PM EDT.&nbsp; Mr. Joyce&rsquo;s presentation will include an update on a forthcoming FDA-cleared
study of the Aethlon Hemopurifier&reg;, a review of the Company&rsquo;s cancer programs, and a progress report on Exosome Sciences,
Inc., a diagnostic subsidiary recently launched by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A live webcast of Mr. Joyce&rsquo;s Wall
Street Analyst Forum presentation can be accessed at the following URL: www.visualwebcaster.com/event.asp?id=99587</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Wall Street Analyst Forum will take
place June 19, 2014 at the University Club of New York, One West 54th Street, New York, NY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Aethlon Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon Medical creates innovative medical
devices to address life-threatening diseases. The Aethlon ADAPT&trade; (Adaptive Dialysis-like Affinity Platform Technology) establishes
the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory
system of treated patients. The lead Aethlon ADAPT&trade; product is the Hemopurifier&reg;, a device that addresses a broad-spectrum
of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating
under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical
device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based
strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About The Wall Street Analyst Forum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Wall Street Analyst Forum has conducted
80+ multiday/multitrack analyst conferences in which over 2500 different NYSE/NASDAQ/AMEX/OTC companies have presented and over
2,000 different institutions have attended in Boston, New York and London since 1989.&nbsp; Public companies ranging from General
Electric, Microsoft Corp., Mattel Inc., Pfizer Inc., Kinross Gold to Genzyme have presented.&nbsp; Institutions ranging from Fidelity
Management, Wellington Management, MFS Investment Management, Pioneer Investment Management, Putnam Management have attended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Certain statements herein may be forward-looking
and involve risks and uncertainties.&nbsp; Such forward-looking statements involve assumptions, known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different
from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA
will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT&trade; system or the Aethlon Hemopurifier&reg; as
an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or
hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products either internally or through outside companies and provide
its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the
Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result
of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors
detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information, future events, or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James A. Joyce<BR>
Chairman and CEO<BR>
858.459.7800 x301<BR>
jj@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes<BR>
Chief Financial Officer<BR>
858.459.7800 x300<BR>
jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marc Robins<BR>
877.276.2467<BR>
mr@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!(`,$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHI*`%IDDL<,;22NJ(HRS,<`?C5/6-
M8M-$T][V\?"+PJCJ[=@*\?\`$'BC4?$,Y-Q(8[<'Y+=#\H^OJ:[,+A)XAW6B
M[G/6KQI>IZ+J/Q$T*Q8I%))>./\`G@OR_P#?1XK';XK1;ODT>0C_`&IP#_*O
M.:*]F&6T(K57."6+JO;0]0M/BCI<KA;JSN;<?WAAQ^G-=7INKZ?JT/FV%W'.
MO<*>1]1U%>"5-:7=Q8W*W%I.\,J='0X-95<KIM?NW9E0QDT_>U/H'-+7(>#O
M&B:X!97VV.^4<8X64>H]#[5UU>'4I3I2<9K4]*$XSCS1%HHHK,L**BN+B&TM
MY+BYE2&&-2SR.V%4#N37-R?$WP7%)Y;>(+8G.,J&8?F!B@#J:*IZ9J^GZS:"
M[TR\ANX"<;XF#`'T/H:K7WB;1=,G\B\U*"*4=4SEA]0.E5&,I.T5<3DH[LU:
M*H0:YI=U8RWT%_!);0J6DD5^$`&23Z<5Q&C_`!7T^[\5ZK9W^H6%MI=L`+2?
M<1YQSUR3S^%)IIV8)IZH]&HKRKXAZNT_BSP5-IM^YM;NX!W0R$)*OF1]<=17
M9ZAX_P#">EW;6EYKEJDR'#(I+[3Z':#BD,Z*BJ>F:MI^LV@N]-O(;N`G&^)L
M@'T/H:\_\&W=S+\8/%5O+<2O#&OR1LY*K\R]!T%`'IE%9^K:[I6A0"?5;^"S
MC8X4RO@M]!U-9^F>._"VL72VMAK=M+.YPL9)0L?0;@,T`=!15:_U&STNRDO;
M^X2WMXL;Y9#A5R<?S-9E_P"-/#6F6L%S>:S:Q17*"2$[LF13T8`<X]Z`-RD)
MP*R-&\6:!X@=H])U6WNI%&3&K88#UVG!H\67S:=X8OKA#A_**(?0MQ_6JA%R
MDHKJ*3Y4V>8>,]??7-:<(Y^R6Q*0@=#ZM^/\JRM,TN\UB]6SL8O,E89ZX"CU
M)["J?05ZW\/]`_LO1A>3IBYO`&.>JI_"/Z_C7TM>K'"4$H^B/&IP=>IJ<=_P
MKCQ%_P`\[;_O]_\`6H_X5QXB_P">=M_W^_\`K5Z[7,_$#Q2GA+PM<7JL/M4H
M\JU4]Y#W_`9/X5Y7]IU_([_J=/S/*=3TN\TB]:TOH3%*HSC.01Z@]Q52E\,Z
MU<>)])N-+O[B2YU&R#7%I)(VYY(^LD>3UQ]X?C25[.$Q'MZ=WOU/.K4O93MT
M)(9I;:=)X7,<L;!D8=017MWAK6EU[18;T8$A^651_"XZ_P"/XUX;7??"R^9;
MR]L"?E=!*H]P<'^8K#,J*G2Y^J-<)4Y9\O<]*HHHKYL]<JZE;V=UI\\&HK$]
MHZ8F64X0K[^U<=<^-_`VGH=/TZVBU*3&!::;9^;N]N!M_6J7QMBOI/"=JUN)
MFLTNE-XL779@X)]L_KBM3P]XK^']C8VMIHU]9VXFVI'"B$2,QX`88R3D]Z`.
M$\`ZE/I5WXVN([,Z>8PKI9]H&+,`,>HS76>%-1TW2]*2672-2N;R?+S7`LS)
MO)]&]*QO"VGC5?&OC^P)P9WV@GL=[8/YUTGAOQ3:Z+8)HNOLUA=6>4!E4[77
M/!!KMHZT9**N[]-['+4TJ)MV5BG'LNO&]O<:?I%W!9W<9AO8Y[4I&X(/4=/2
ML?P;H>DW/Q4\5VD^EV<MO!CRH7@4I'\W8$8%>B:?XITC5K[['I]U]IDV%R40
M[5`]2?K7FFF>(].\(?%[Q,^N2/:17F#%(8V8'H1T&<$=ZQKRDVE*-K(TI123
ML[A\8=/!U[PGIVGA;3<[10^4-HBRZ`8`Z8S7H5AX$\,:?IPL4T6SE3;AGFA5
MW<^I8C.:X'XA:C;:OXJ\":A9.9+>XN`\;E2,CS(^<&O7JP-CRCX=VD>A?%;Q
M-H=B62Q2/>D18D*<J1^6XBI_!/\`R6?Q=_N?^S+2>%/^2Z>)_P#KA_\`&Z7P
M5Q\9_%W^Y_[,M`%?P=80>/?'.NZ]K<0NX;"?[/9V\HW1H,GMT/`'XDFNE\>>
M"-&U7PQ>RQV%O;7EK"TT$\,81E91G&1U!Q7,:?>_\*L\;ZM%JT,JZ)J\OG07
M:(66-LDX./\`>(]>`:TO%WQ-TB\T6?2?#4SZKJ=_&88H[>)CLW#!)R/0]*`,
MNYUV?Q!^S[<W5VYDN(E6"1SU8K(H!/OC%;'PT\%Z5_PBMCJNIV<5_?7D0?S+
ME!)Y<?1%4'@`*!5#6?#LGA?X#7.F3X^T!$DGQR`[2*2/PZ?A7:^!/^1$T3_K
MRB_]!%`'GGCG2+'PO\1_"NH:+;I927=P$E2$;4;YU!X'3(<@UW/Q&S_PB,V/
M^>J9_.N3^+/_`".G@O\`Z^__`&I'7>^*[!M2\,WUM&I:0QED`ZEAR!^E;4)*
M-6+?=&=57@TCR[P;H7]NZ[&DBYMH/WDWH1V7\3_6O:%``P``!6!X,T(:'H4:
M2+BYGQ)-Z@GHOX#^M=!6^-K^VJZ;+8RPU+V<-=V)7S;\6/%A\2>*I+>!R;+3
MB88AV9L_.WXD8^@KVWQSKW]BZ&R0OBZNLQQ>JC^)OP'\Z^=O$MAY4PNXU^63
MA_9O_KUG'#3=%UNB+=:*J>S,[2=3N-&U2VU&T;;/;2!T/8X['V(X_&O1M32V
MD,&I6`Q8Z@GG0C^X>C(?=6R/RKRZNW\!ZA_:%K<>&)W^>4FXT\GM,!\R?\#4
M?F!6F"K^QJZ[/<C$TO:0TW1<KK?AKG_A*^,X^SOG]*Y/D<$8([5WOPLL6:\O
M;\CY401*?<G)_D/SKWL;)1P\KGFX=7JQ/2J***^4/;$90P(8`@C!![U3CT?2
MX91-%IMI'(#D.L"A@?7.*NT4`,6&-&9DC16;[Q`P3]:9-:V]P`)X(I<=-Z!O
MYU-10%B**V@@&(88XQZ(H7^51W.G6-XRM=65O.R\`RQ*Q'YBK-)0!0GNM+M+
MNTL9O)CFER+>,IUQZ<<4R3Q%I,1NP]X@-D0+C@GRR3@9X]:S/$VD7M_?0W5G
M&&DM8&>%BP'[T.C`?B`161)X9U1=-U)!;[[B[@A9B'`W2^87?\L_I753I4I1
M3E+^K_Y'/*I--I(Z4>(-#2&2^$RH@=4:0PL"6/0=,GI2PZ]HCP7%['<1!8<>
M>VPJRY/&1C-9%W9ZG<:5$B65Z\L%[#-MN;A'9E4Y."#@=*BU72-5U@:C>FQ%
ML\MLEO#`9%+OAPQ9B.![4U2IO=_BO('4GT1O:AK.CPR&SO94D9E#-#Y9DP#T
M)`!Q^-`ET+2;^"UCCM+2YNO]6L<04O\`D/YUGVT&HZ-JU_,FFO>Q7SI(KQ2*
M&0A0-K!B...,50O?#FK:JU_J<DK6UV7'V6WPK#;'RF6[9.3P>]2J=-O5Z=QN
M<[:+4ZJ.[L[V6XM49)7MV"S(1G:2,C.:G^2*/``55'0#``KF=+_M6QU6_N9]
M(E*7SQN621,1X0!L\]CFMVUNFU#31.()(?-4[4D&&QT!([9K*<.5Z;:%QG=>
M96&MZ+<S6:FXA>2[!-MN7E\'G&1ZBIIM:TZWAGEFND1+>3RI">S_`-WW//:N
M6MO"EU<VVG6]Y$8?(LI$,BL"89?,#(1^6:6#1=<,*7MU:Q/>0:C]I:`.`LPV
M!<@]`>,C-;NE2_F_K^ON,O:5.QUMAJ%MJ432VKLRJVT[D92#]"!5AW5%+,0%
M49)/850M[^]E6-FTF:'?+L822)E%Q][@GC/&.M87Q$U6>PT'[/!&_P#I9V/*
M`<(O<9[$]/SK*%)SJ*"ZFDJBC!R9Y_XKUPZ]KDMPI/V>/]W`/]D=_P`>M<_=
MVR7=K)!)T<8SZ'L:FHKZR-*,8<BVV/%<VY<W4X">![>=X9!AT.#2VUQ-9W45
MS;R&.:%PZ.IY5@<@UV-WH]E>S>=-&V\C!*MC-):>$;:_N5MK2UGFE?HB,2:\
M&IEE1-M-6/3CC(-*Z=SH)\:_#9:QI\.3J9VR0H/]7<#AU^A/S#V->P>&M%30
M=%@LA@R`;I6'\3GK_A^%8?@#P+'X1LI#([//<,':,MN2(@$<?[6"0378USU\
M3*<%2;T7XFE*C&,G-=1:***XSH"BBB@`HHHH`****`$Q1110`8%&***`#%%%
M%`!@4444`%%%%`!BFR11RQM'(BNC#!5AD'\***`.7U'X=Z#?,SPQR6;G_G@W
MR_\`?)XK(?X4Q;ODUB0#_:@!/\Z**Z8XW$05E(Q>'I2U:+=I\+]+B<-=7ES<
MX_A&$'Z<UU6G:1I^DP^586D<"]RHY/U/4T45%3$5:OQRN5"E"'PHN4M%%8F@
&4444`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
